Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12091666 | 0.79 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL24692277 | 0.78 | — | — | |
| SCHEMBL12590858 | 0.77 | — | — | |
| SCHEMBL16719966 | 0.75 | — | — | |
| SCHEMBL2183850 | 0.73 | CYP1A2 (0.30) | — | |
| SCHEMBL21849410 | 0.71 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL278294 | 0.69 | — | — | |
| SCHEMBL4338960 | 0.69 | TBXAS1 (0.49) | TSHRTDP1 | |
| SCHEMBL27687972 | 0.69 | — | — | |
| SCHEMBL24035225 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| CN-102807520-A | Ionic liquid and power storage device including the same | SEMICONDUCTOR ENERGY LAB | 2012-12-05 | — | — | CN | disclosed |
| US-8133898-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-13 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-4906758-A | Preparation of pyrroles from dialkoxytetrahydrofurans | BASF AKTIENGESELLSCHAFT (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0303206-A2 | Process for the preparation of pyrroles | BASF Aktiengesellschaft (DE) | 1989-02-15 | — | — | EP | disclosed |
| EP-0125415-B1 | PROCESS FOR THE PRODUCTION OF PYRROLES | BASF Aktiengesellschaft (DE) | 1986-11-26 | — | — | EP | disclosed |
| US-4560769-A | CATALYTIC CYCLIZATION OF AMMONIA OR AMINE WITH BUT-2-ENE-1,4-DIOL | BASF AKTIENGESELLSCHAFT (DE) | 1985-12-24 | — | — | US | disclosed |
| EP-0125415-A1 | Process for the production of pyrroles | BASF Aktiengesellschaft (DE) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | TSHR 3729/4885TDP1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.